drugset / Trial / NCT06694389
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
Timeline
- Start
- 2024-11-18
- Primary completion
- 2025-11-17
- Completion
- 2025-11-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Licensed influenza vaccine | Vaccine | — | Subcutaneous |
| Comparator | SARS-CoV-2 Vaccine | Vaccine | — | Intramuscular |
| Subject | mRNA-1083 | Messenger RNA (mRNA) | — | Intramuscular |